Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Personalis, Inc.

NASDAQ: PSNL · Industrial Applications and Services · 5 alerts · CIK 1527753

Share price
$14.80Close, Nov 16
Market cap
$1.6B
Shares outstanding
108.4MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Personalis, Inc. filings on SEC EDGAR ↗

4:15 PM ET Form 4
Insider Selling

Personalis CEO Christopher M. Hall Sells $462K of Stock

Christopher M. Hall, CEO, sold 29,112 shares of Personalis, Inc. at $15.87 a share, worth $462K in total on Nov 3, 2026. Shares held after the trade: 199,415 (-12.7%).

Value
$462K
Shares
29,112
Price
$15.87
Role
CEO
Holding change
-12.7%
Trade date
Nov 3, 2026
4:06 PM ET 8-K
Financial Results

Personalis Financial Results

Personalis reported Q3 2026 total revenue of $25.6 million, a significant increase from $14.5 million in the prior year, driven by growth in clinical test volume and population sequencing. The company ended the quarter with $190.6 million in cash and noted its pending merger with Tempus AI. Due to the pending acquisition, the company is no longer providing forward-looking financial guidance.

“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners.”

Chris Hall, Chief Executive Officer of Personalis
4:06 PM ET 10-Q
Financial Results ▶ Call

Personalis Q3 2026 Results: Net Loss of $33.8M, Loss Widens

Personalis, Inc. has entered into a definitive merger agreement to be acquired by Tempus AI, Inc. The company continues to report a history of losses and maintains significant customer concentration with Moderna, the VA MVP, and Merck while focusing on its partner-centric strategy for cancer testing services.

Key figure
Net loss $33.8M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.